Tempest Therapeutics

Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study
Benzinga
Mon, 05/1/23 - 10:22 am
Tempest Therapeutics
TPST-1120
clinical trials
metastatic hepatocellular carcinoma